Teduglutide (Gattex)
Teduglutide is a recombinant analog of glucagon-like peptide-2 (GLP-2) with a Gly2 substitution that resists DPP-4 degradation, extending its activity relative to native GLP-2. It acts on GLP-2 receptors in the gut to increase villus height, crypt depth, and mucosal blood flow, which enhances fluid and nutrient absorption. This reduces the volume of parenteral support needed in short bowel syndrome. Because it is trophic to intestinal tissue, the label advises surveillance for neoplasia.
Metabolic effects build over days to weeks of consistent use.
Store the lyophilized powder refrigerated (2 to 8 C), or frozen for long-term storage, protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within about 4 weeks.
Clinical Evidence
What the literature says
Scientific Overview
According to PubMed, a population-PK and exposure-response analysis across 219 patients found teduglutide 0.05 mg/kg daily produced a maximum reduction in parenteral support of about 5.76 L/week, with an elimination half-life near 1.47 hours in short bowel syndrome (Marier JF et al., Clin Transl Sci 2021). It is FDA-approved (Gattex/Revestive) and well characterized by its label.
Pharmacokinetics
- Half-life (t½)
- 1.5 h
- Approximate plasma half-life
- Routes
- Subcutaneous
Citations (2)
Last reviewed: 2026-06-15
Research Guide
How users approach this compound
The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.
Typical Dose Range Observed
Research Protocols
Common DosagesShort bowel syndrome (label)
“Per FDA labeling; rotate injection sites”
Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.
Reported Uses
- Short bowel syndrome dependent on parenteral support (approved)
- Investigational interest in other malabsorptive states
Key Research Benefits
- Increases intestinal villus height and crypt depth, improving absorption
- Reduces dependence on parenteral nutrition and IV fluids in short bowel syndrome
- Approved for both adult and pediatric short bowel syndrome
Potential Side Effects
Considerations and Cautions
- Active or suspected gastrointestinal malignancy
- History of GI cancer within the past 5 years (label caution)
- Hypersensitivity to teduglutide
Labs to monitor
Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.
- Colonoscopy / colorectal surveillance: GLP-2 is trophic to intestinal tissue; the label advises neoplasia surveillance.
- Fluid and electrolyte status: Improved absorption can cause fluid overload and shifts requiring parenteral-support adjustment.
- Bilirubin / lipase / amylase: Label advises monitoring for biliary and pancreatic disease.
Dose Calculator
Peptide Reconstitution Calculator
Total amount of peptide in the vial.
Volume of water used to mix.
Draw to this mark
or 0.10 mL on a U-100 syringe
Teduglutide (Gattex) by goal
Read Teduglutide (Gattex)'s profile filtered through specific research goals.
Related Tools
Not medical advice
Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.